FDA’s initial vision for a compendium of clinical outcomes assessment tools includes instruments that have completed or are undergoing the agency’s formal qualification process as well as measures reflected in labeling for novel products.
However, the agency hopes to eventually broaden the scope of the compendium to include instruments that were submitted as part of efficacy supplements